Ony Biotech

Executive Summary

Ony Biotech is a privately held U.S. biotechnology company dedicated exclusively to neonatology. The company's lead product, Infasurf® (calfactant), is a lung surfactant approved for the prevention and treatment of respiratory distress syndrome (RDS) in premature infants. Leveraging deep expertise in surfactant biology and neonatal care, Ony Biotech aims to expand its portfolio with novel drug delivery systems and devices tailored to vulnerable newborns. Despite operating in a niche market with high unmet need, the company faces competition from established surfactants and generics. Ony Biotech's success hinges on its ability to innovate beyond Infasurf, potentially through next-generation formulations or combination products that improve administration and outcomes. The company's private status limits visibility, but its focused strategy positions it for targeted growth within neonatology.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of a new surfactant formulation or delivery device40% success
• TBDAnnouncement of a strategic partnership with a larger pharmaceutical company60% success
• Q4 2025Completion of a Series B or later financing round70% success